NCT03375320 2026-03-18Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNational Cancer Institute (NCI)Phase 3 Active not recruiting298 enrolled 14 charts 1 FDA
NCT02831179 2017-09-28Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorVanderbilt-Ingram Cancer CenterPhase 1 Withdrawn